Tyng-Yuan Jang, Po-Cheng Liang, Dae Won Jun, Jang Han Jung, Hidenori Toyoda, Chih-Wen Wang, Man-Fung Yuen, Ka Shing Cheung, Satoshi Yasuda, Sung Eun Kim, Eileen L Yoon, Jihyun An, Masaru Enomoto, Ritsuzo Kozuka, Makoto Chuma, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Masanori Atsukawa, Taeang Arai, Korenobu Hayama, Masatoshi Ishigami, Yong Kyun Cho, Eiichi Ogawa, Hyoung Su Kim, Jae-Jun Shim, Haruki Uojima, Soung Won Jeong, Sang Bong Ahn, Koichi Takaguchi, Tomonori Senoh, Maria Buti, Elena Vargas-Accarino I, Hiroshi Abe, Hirokazu Takahashi, Kaori Inoue, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Chung-Feng Huang, Wan-Long Chuang, Mindie H Nguyen, Ming-Lung Yu
BACKGROUND AND AIM: The benefits of entecavir (ETV) versus tenofovir disoproxil fumarate (TDF) in reducing the development of chronic hepatitis B (CHB)-related hepatocellular carcinoma remain controversial. Whether mortality rates differ between patients with CHB treated with ETV and those treated with TDF is unclear. METHODS: A total of 2542 patients with CHB treated with either ETV or TDF were recruited from a multinational cohort. A 1:1 propensity score matching was performed to balance the differences in baseline characteristics between the two patient groups...
March 13, 2024: Journal of Gastroenterology and Hepatology